乳腺癌他莫昔芬耐药机制的研究进展

doi:10.11904/j.issn.1002-3070.2017.02.013

摘要/Abstract

摘要： 他莫昔芬(Tamoxifen,TAM)对于治疗雌激素受体(ER)阳性的乳腺癌是一种重要的治疗策略。然而TAM耐药是内分泌治疗失败的一个主要原因。TAM耐药的潜在机制是多因素的,其中大部分仍是未知的。本文介绍了近年来有关乳腺癌TAM耐药机制的研究进展,为阐明TAM耐药机理及克服耐药性提供有价值的信息和思路。

关键词: 他莫昔芬, 乳腺癌, 雌激素受体, 耐药

Abstract: Tamoxifen(TAM)is an important therapeutic strategy for the treatment of estrogen receptor(ER)-positive breast cancer.However,tamoxifen resistance is a major cause of endocrine therapy failure.The potential mechanism of TAM resistance is multifactorial and most of them are still unknown.This review presents recent advances in the mechanism of TAM resistance in breast cancer,providing valuable information and ideas for elucidating the mechanism of tamoxifen resistance and overcoming drug resistance.

Key words: Tamoxifen, Breast cancer, Estrogen receptors, Resistance

中图分类号:

R737.9

于飞, 胡晶(综述), 陈雪松(审校). 乳腺癌他莫昔芬耐药机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 160-164.

YU Fei,HU Jing,CHEN Xuesong. Research progress of tamoxifen resistance mechanism in breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 160-164.

参考文献

1 Ojo D,Wei F,Liu Y,et al.Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion[J].Curr Med Chem,2015,22(19):2360-2374.
2 Nass N,Kalinski T.Tamoxifen resistance:From cell culture experiments towards novel biomarkers[J].Pathol Res Pract,2015,211(3):189-197.
3 Yin L,Pan X,Zhang XT,et al.Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen[J].American Journal Cancer Research,2015,5(2):530-544.
4 Droog M,Beelen K,Linn S,et al.Tamoxifen resistance:From bench to bedside[J].Eur J Pharmacol,2013,717(1-3):47-57.
5 Early Breast Cancer Trialists′ Collaborative Group,Davies C,Godwin J,et al.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:Patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.
6 Pietras RJ,Marquez-Garban DC.Membrane-associated estrogen receptor signaling pathways in human cancers[J].Clin Cancer Res,2007,13(16):4672-4676.
7 Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells[J].Cancer Res,2001,61(19):7025-7029.
8 Fuqua SA,Wiltschke C,Zhang QX,et al.A hypersensitive estrogen receptor-α mutation in premalignant breast lesions[J].Cancer Res,2000,60(15):4026-4029.
9 Toy W,Shen Y,Won H,et al.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J].Nat Genet,2013,45(12):1439-1445.
10 Merenbakh-Lamin K,Ben-Baruch N,Yeheskel A,et al.D538G mutation in estrogen receptor-α:A novel mechanism for acquired endocrine resistance in breast cancer[J].Cancer Res,2013,73(23):6856-6864.
11 Jeselsohn R,Yelensky R,Buchwalter G,et al.Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer[J].Clin Cancer Res,2014,20(7):1757-1767.
12 Niu J,Andres G,Kramer K,et al.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients[J].Onco Targets Ther,2015,11(8):3323-3328.
13 Robinson DR,Wu YM,Vats P,et al.Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J].Nat Genet,2013,45(12):1446-1451.
14 Yu T,Liu M,Luo H,et al.GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells[J].Steroid Biochem Mol Biol,2014,9(143):392-403.
15 Mo Z,Liu M,Yang F,et al.GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer[J].Breast Cancer Res,2013,15(6):R114.
16 Ignatov A,Ignatov T,Weissenborn C,et al.G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer[J].Breast Cancer Res Treat,2011,128(2):457-466.
17 Pupo M,Pisano A,Abonante S,et al.GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts(CAFs)[J].Int J Biochem Cell Biol,2014,1(46):56-67.
18 Rakha EA,El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
19 Ciupek A,Rechoum Y,Gu G,et al.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer[J].Breast Cancer Res Treat,2015,154(2):225-237.
20 Cochrane DR,Bernales S,Jacobsen BM,et al.Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide[J].Breast Cancer Res,2014,16(1):7.
21 Ramaswamy B,Lu Y,Teng KY.et al.Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant brest cancer aberrantly activated by PI3K/AKT pathway[J].Cancer Res,2012,72:5048-5059.
22 Matevossian A,Resh MD.Hedgehog acyltransferase as a target in estrogen receptor positive,HER2 amplified,and tamoxifen resistant breast cancer cells[J].Mol Cancer 2015,4(14):72-87.
23 Villegas VE,Rondon-Lagos M,Annaratone L,et al.Tamoxifen treatment of breast cancer cells:Impact on Hedgehog/GLI1 signaling[J].Int J Mol Sci,2016,17(3):308-320.
24 O′Toole SA,Machalek DA,Shearer RF,et al.Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer[J].Cancer Res,2011,71(11):4002-4014.
25 Noman AS,Uddin M,Rahman MZ,et al.Overexpression of Sonic Hedgehog in the triple negative breast cancer:Clinicopathological characteristics of high burden breast cancer patients from bangladesh[J].Sci Rep,2016,1(6):18830-18841.
26 Van Schooneveld E,Wildiers H,Vergote I,et al.Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patientmanagement[J].Breast Cancer Res,2015,2(17):21-36.
27 Garofalo M,Quintavalle C,Romano G,et al.miR221/222 in cancer:Their role in tumor progression and response to therapy[J].Curr Mol Med,2012,12(1):27-33.
28 Lu Y,Roy S,Nuovo G,et al.Anti-microRNA-222(anti-miR-222)and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal[J].Biol Chem,2011,286(49):42292-42302.
29 Sachdeva M,Mo YY.MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1[J].Cancer Res,2010,70(1):378-387.
30 Shi W,Gerster K,Alajez NM,et al.MicroRNA-301 mediates proliferation and invasion in human breast cancer[J].Cancer Res,2011,71(8):2926-2937.
31 Ward A,Shukla K,Balwierz A,et al.MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer[J].Pathol,2014,233(4):368-379.
32 Hoppe R,Achinger-Kawecka J,Winter S,et al.Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment[J].Eur J Cancer,2013,49(17):3598-3608.
33 Zhang W,Xu J,Shi Y,et al.The novel role of miRNAs for tamoxifen resistance in human breast cancer[J].Cell Mol Life Sci,2015,72(13):2575-2584.
34 Li CH,Chen Y.Targeting long non-coding RNAs in cancers:Progress and prospects[J].Int J Biochem Cell Biol,2013,45(8):1895-1910.
35 Hayes EL,Lewis-Wambi JS.Mechanisms of endocrine resistance in breast cancer:An overview of the proposed roles of noncoding RNA[J].Breast Cancer Res,2015,5(17):40.
36 Su X,Malouf GG,Chen Y,et al.Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes[J].Oncotarget,2014,5(20):9864-9876.
37 Xue X,Yang YA,Zhang A,et al.LncRNA HOTAIR enhanceser signaling and confers tamoxifen resistance in breast cancer[J].Oncogene,2016,35(21),2746-2755.
38 Xing Z,Lin A,Li C,et al.LncRNA directs cooperative epigenetic regulation downstream of chemokine signals[J].Cell,2014,159(5):1110-1125.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[9]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[10]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[11]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[12]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[13]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[14]	王笑笑, 华腾, 汪宏波. 雌激素受体相关受体γ在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 87-91.
[15]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.